CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
Go back to CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia| (NASDAQ: CRVO) | Delayed: 2.53 -0.04 (1.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.57 | 52 Week High | $ | |||
| Open | $2.54 | 52 Week Low | $ | |||
| Day High | $2.58 | P/E | N/A | |||
| Day Low | $2.49 | EPS | $ | |||
| Volume | 128,294 | |||||
